Papers
2
Total Citations
24
H-Index
2
About
Dr. Shanky Singh is a rising urologic oncologist whose research is reshaping the management of prostate cancer, particularly in the Indian context. His work focuses on two critical frontiers: advancing non-invasive diagnostic pathways and challenging established treatment paradigms for low-risk disease. Dr. Singh’s most impactful contribution is his pioneering investigation into a biopsy-free diagnostic pathway for localized prostate cancer. His landmark 2023 study, which has already garnered 14 citations, demonstrated the combined accuracy of multi-parametric MRI and PSMA PET-CT, suggesting that for select patients, these advanced imaging modalities may reliably replace the need for an invasive biopsy—a potential paradigm shift in clinical practice. Complementing this work, his 2020 study (10 citations) directly addressed a contentious issue in Asian oncology: the validity of active surveillance for low-risk prostate cancer in India. By questioning whether the traditionally aggressive disease course in Indian males renders active surveillance unsafe, Dr. Singh has sparked a vital re-evaluation of treatment strategies, advocating for evidence-based, patient-specific care. Through these contributions, Dr. Singh is not only advancing precision diagnostics but also tailoring global best practices to regional realities, marking him as a key voice in the future of prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2